Glucagon-like Peptide-1 Agonists Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Glucagon-like Peptide-1 Agonists Market Trends and Insights

Rising Prevalence of Type-2 Diabetes

International Diabetes Federation projections show diabetes cases climbing from 537 million in 2021 to 783 million by 2045, with 90% classified as type-2^{[1]International Diabetes Federation, “IDF Diabetes Atlas, 10th Edition,” diabetesatlas.org}. Incidence is accelerating fastest across urbanizing Asia-Pacific economies, where lifestyle changes and aging populations converge. China alone documented a 12.4% adult prevalence in 2024, translating into more than 140 million individuals who often remain undertreated. The American Diabetes Association upgraded GLP-1 agonists to preferred second-line agents for patients with cardiovascular comorbidities in its 2024 Standards of Care, elevating the drug class above sulfonylureas and DPP-4 inhibitors for many clinical scenarios. As payers shift toward value-based models, the capacity of GLP-1 agonists to reduce microvascular and macrovascular complications strengthens formulary support, boosting the glucagon-like peptide-1 (GLP-1) agonists market well into the next decade.

Escalating Obesity Epidemic and Weight-Loss Approvals

World Health Organization data confirm that worldwide obesity prevalence nearly tripled between 1975 and 2024, affecting more than 890 million adults. Regulatory momentum is matching the epidemiologic urgency. Eli Lilly’s tirzepatide gained FDA clearance for chronic weight management in late 2023, followed by European approval in early 2024, breaking Wegovy’s early monopoly. In pivotal SURMOUNT-1 data, tirzepatide produced a 20.9% mean weight reduction, outperforming semaglutide’s 14.9% STEP-1 result. The FDA endorsement of semaglutide for obstructive sleep apnea in 2025 further widened the eligible population, encouraging Medicare Advantage plans to drop previous exclusions. Collectively these approvals have catalyzed a surge of obesity prescriptions that now form the single fastest-growing revenue stream inside the glucagon-like peptide-1 (GLP-1) agonists market.

Physician Shift to Once-Weekly GLP-1s

Real-world data show weekly formulations improve persistence by 28% compared with daily injections, translating to superior glycemic and weight outcomes. Prescription volume for semaglutide (Ozempic) climbed 35% year on year in the United States during 2024, largely due to migration from daily agents. Payers reinforce the shift through tier placement that favors once-weekly options, recognizing downstream cost savings. The GLP-1 agonists market therefore continues to tilt toward long-acting injectables, anchoring semaglutide and tirzepatide at the forefront while relegating older daily products to niche status.

Reimbursement and Guideline Expansion

The Centers for Medicare & Medicaid Services mandated that Part D formularies include at least two GLP-1 agonists per administration route from March 2024 onward, curbing historical exclusion practices. Commercial payers followed quickly; UnitedHealthcare eliminated step edits for eligible cardiovascular or renal-risk patients in May 2024. Clinical evidence such as the SELECT outcomes trial, which delivered a 20% reduction in major cardiovascular events among obese adults without diabetes, underpins these policy shifts. The resulting alignment between guidelines and reimbursement accelerates specialist and primary-care adoption, expanding the GLP-1 agonists market to previously untapped populations.

High Therapy Cost and Limited Obesity Coverage

Annual U.S. wholesale acquisition costs range from USD 13,000 to USD 16,000, leaving uninsured and Medicare beneficiaries without diabetes exposed to full list prices^{[2]Kaiser Family Foundation, “Employer Health Benefits Survey 2024,” kff.org}. Only 38% of employer plans covered anti-obesity drugs in 2024; even then, prior authorizations and spending caps remain common. Novo Nordisk’s savings card caps Wegovy copays at USD 500 but does not address the 65-plus population excluded by statute. Across India, median household income of USD 2,400 renders branded GLP-1 therapy out of reach, steering demand toward forthcoming biosimilars. Thus pricing and coverage barriers temper overall GLP-1 agonists market expansion, particularly in obesity-only indications.

Gastro-Intestinal Side Effects and Discontinuation

Real-world data covering 200,000 patients show 42% reporting at least one gastrointestinal event within three months of therapy initiation, with 15% discontinuation by year one. The FDA added a boxed warning to tirzepatide in June 2024, spotlighting severe gastroparesis risk but noting benefits outweigh harms. Dose titration, concurrent antiemetics, and next-generation co-formulations aim to mitigate symptoms, yet side-effect-driven drop-outs continue to moderate real-world uptake, shaving incremental points off the GLP-1 agonists market CAGR in the near term.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Molecule: Tirzepatide Narrows Semaglutide’s Lead

Semaglutide generated 42.56% of 2025 revenue, anchoring the glucagon-like peptide-1 agonists market through its dual diabetes-obesity branding and extensive outcomes data. Tirzepatide’s 25.25% CAGR to 2031 reflects dual GIP/GLP-1 agonism that delivers larger HbA1c and weight reductions, bolstered by Lilly’s discounting strategy that undercuts Wegovy list prices. The GLP-1 agonists market size for tirzepatide could reach USD 38 billion by 2031 if current trial data readouts remain positive and capacity expansions stay on schedule. Dulaglutide and liraglutide are sliding into twilight phases as payer formularies migrate toward higher-efficacy weekly drugs. Meanwhile, retatrutide’s early-stage data suggest even greater weight-loss potential, indicating a pipeline that could further reshape molecule-level rankings within the GLP-1 agonists market. 

Second-generation agents exenatide and lixisenatide now serve price-sensitive geographies or patients intolerant to stronger compounds. Biosimilar liraglutide filings in China and India may pressure pricing in value segments, but are unlikely to displace branded products in premium markets that demand proven outcomes data. As a result, the GLP-1 agonists industry remains a two-player race at the molecule level, with semaglutide and tirzepatide setting efficacy benchmarks that newer entrants must match or exceed.

By Route of Administration: Oral Formulations Gain Momentum

Weekly injectables held 65.53% of 2025 revenue, reflecting physician comfort and patient familiarity. Oral semaglutide’s 48% sales growth during 2024 proved primary-care appetite for non-injectable incretins, especially among injection-averse or newly diagnosed patients. The glucagon-like peptide-1 agonists market share for oral products remains modest today, yet pipeline candidates such as GSBR-1290 and danuglipron aim to match injectable efficacy without requiring absorption enhancers. If successful, oral entrants could capture double-digit market share by decade-end, providing a potent convenience advantage.

Daily injectable formats are rapidly contracting. Saxenda prescriptions declined 12% year on year as obesity prescribers pivoted to once-weekly options, illustrating how dosing frequency shapes patient preference. Longer-acting monthly injectables like maridebart cafraglutide are in Phase 2 development and, if approved, could further tilt adherence benefits toward ultra-long-acting regimens, ultimately enlarging the GLP-1 agonists market size in maintenance therapy segments.

By Indication: Obesity Surges Past Diabetes Growth

While type-2 diabetes still produced 57.63% of 2025 sales, obesity prescriptions are advancing at a 30.87% CAGR through 2031. This fast climb owes to broader societal focus on weight management and payer realization that sustained weight loss lowers downstream cardiovascular costs. The glucagon-like peptide-1 agonists market size tied to obesity could eclipse USD 50 billion by 2031 at current acceleration rates. Cardiovascular prevention now forms a third revenue pillar after the 2024 FDA approval enabling semaglutide use in overweight adults with heart disease. New sleep apnea and potential NASH indications further widen therapeutic reach, ensuring multi-specialty penetration that deepens prescriber pool and increases lifetime patient value. 

Durability data from SURMOUNT-3 indicate tirzepatide maintains weight loss beyond initial lifestyle interventions, fueling payer confidence in long-term cost offsets. As wider cholesterol-lowering, renal-protection, and potentially cognitive benefits emerge, indication stacking will keep the glucagon-like peptide-1 (GLP-1) agonists market on an upward revenue slope even as individual categories mature. 

Geography Analysis

North America maintained 41.13% of 2025 revenue, supported by early approvals, high prevalence of obesity, and premium pricing. Adoption has now moved from specialist to primary-care settings, yet unit growth is plateauing as coverage widens and competition intensifies. Inflation Reduction Act price negotiations, effective 2027, will reduce average selling price but boost volume, providing net positive revenue stability for the glucagon-like peptide-1 (GLP-1) agonists market in the region. 

Europe accounted for 28% of global sales in 2025. Centralized approvals speed multinational launches, but national cost-effectiveness reviews temper revenue per patient. Germany’s positive benefit rating for tirzepatide enabled higher negotiated pricing, whereas the United Kingdom’s narrower BMI eligibility dampens total addressable population. Continued reimbursement expansion tied to cardiovascular and renal outcomes is likely to drive mid-single-digit volume growth, preserving Europe as a solid, though mature, profit pool. 

Asia-Pacific, recording the fastest 18.81% CAGR, is set to shift the global revenue mix as China, Japan, and India unlock large patient cohorts. China’s late-2024 tirzepatide approval and accompanying USD 1 billion local manufacturing commitment highlight strategic focus on domestic capacity that supports rapid volume ramp-up^{[3]National Medical Products Administration, “Tirzepatide Approval for Type 2 Diabetes,” nmpa.gov.cn}. Japan’s first-in-class obesity approval in early 2024 delivered strong initial uptake; local insurers are now reevaluating reimbursement ceilings, which should foster sustained growth. As regional governments confront soaring cardiometabolic disease costs, broader subsidization is expected, advancing the glucagon-like peptide-1 (GLP-1) agonists market toward leadership status in Asia-Pacific by the early 2030s.

Regulatory Landscape

Regulation for GLP-1 agonists is tightening around product quality, lawful supply, and label governance as demand expands across diabetes and obesity. In the United States, the FDA shifted from shortage-era flexibility toward enforcement in 2026, including a February 2026 announcement to restrict use of non-FDA-approved GLP-1 active pharmaceutical ingredients in compounded products and an April 2026 clarification of compounding policies under sections 503A and 503B as national supply began stabilizing. The FDA also requested removal of suicidal ideation and behavior labeling language for GLP-1 receptor agonists in April 2026 following a comprehensive review, reflecting how post-market safety evaluation continues to shape prescribing confidence.

In Europe, centralized review continues to move line extensions and new formats forward while providing a clearer pathway for follow-on products. In May 2026, EMA's CHMP issued a positive opinion recommending marketing authorization for an oral semaglutide formulation (Wegovy tablets) for weight management, reinforcing regulatory support for oral delivery platforms. The same month, CHMP issued a positive opinion for Ablymico (a hybrid medicine of liraglutide) from STADA Arzneimittel AG, indicating maturing EU pathways for hybrid and biosimilar-like competition in first-generation molecules, alongside continued manufacturing-compliance scrutiny across global supply chains.

Market Opportunities and Future Outlook

Oral GLP-1 formats are creating an expansion lane that links product innovation with manufacturing investments and regulatory progress. EMA's May 2026 CHMP positive opinion for Wegovy tablets provides a near-term European anchor for oral semaglutide commercialization, and Novo Nordisk followed the oral pivot with a March 2026 announcement of a 432 million euro expansion at its Athlone, Ireland facility specifically for oral GLP-1 treatments. Together, these moves support broader participation by payers and primary-care channels where injection aversion and adherence barriers have historically constrained uptake.

Manufacturing scale-up and localization are also a key whitespace enabler, especially in price-sensitive regions and for future value-tier competition. In March 2026, Neuland Laboratories announced plans for a peptide CMC facility in Bonthapally, India designed to produce GLP-1s with room for expansion, complementing originator-led investment and strengthening the API and intermediate supply base. At the same time, FDA actions in 2026 to restrict non-approved compounded GLP-1 APIs and clarify lawful compounding requirements concentrate demand back toward approved products and compliant supply chains, creating space for contract manufacturing, serialization and cold-chain services, and regulated follow-on competition focused on availability and cost of goods rather than grey-market substitutes.